ID   9F3.18.5
AC   CVCL_F1WG
SY   9F3
DR   ABCD; ABCD_BG479
RX   Patent=US8557967;
RX   PubMed=11594789;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2917.
CC   Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized rontalizumab (9F3v13) therapeutic antibody which was designed to target and block the effects of interferon-alphain patients with autoimmune diseases like systemic lupus erythematosus (SLE).
CC   Monoclonal antibody isotype: Not specified.
CC   Monoclonal antibody target: Human alpha-interferons.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_3412 ! P3X63Ag8U.1
CA   Hybridoma
DT   Created: 27-11-25; Last updated: 27-11-25; Version: 1
//
RX   Patent=US8557967;
RA   Chuntharapai, Anan
RA   Kim, Kyung Jin
RA   Presta, Leonard G.
RA   Stewart, Timothy A.
RT   "Anti-interferon-alpha antibodies.";
RL   Patent number US8557967, 15-Oct-2013.
//
RX   PubMed=11594789; DOI=10.1006/cyto.2001.0934;
RA   Chuntharapai, Anan
RA   Lai, Jadine
RA   Huang, Xiao-Jian
RA   Gibbs, Verna C.
RA   Kim, Kyung Jin
RA   Presta, Leonard G.
RA   Stewart, Timothy A.
RT   "Characterization and humanization of a monoclonal antibody that
RT   neutralizes human leukocyte interferon: a candidate therapeutic for
RT   IDDM and SLE.";
RL   Cytokine 15:250-260(2001).
//